Selling by month
Oct 2025 to Oct 2026. Each sale is counted once: under a disclosed plan, else to cover taxes, else no plan disclosed.
Disclosed planOne dollar scale for every month; the tallest bar is labeled
Pattern
What the filings show, past 12 months. Nothing here rates or predicts.
- Sold in 2 of the 13 calendar months from Oct 2025 to Oct 2026: Dec 2025 and Aug 2026.
- Largest single sale: $1.0M (10,000 shares) of Spyre Therapeutics, Inc. on Aug 7, 2026. Filing
- Last sale before this period: Oct 13, 2025.
Roles from filings
Every company we track where this person has filed, newest filing first.
| Company | Title | First filing | Latest filing |
|---|---|---|---|
| Spyre Therapeutics, Inc. (SYRE) | Director | Nov 27, 2023 | Aug 10, 2026 |
| Kymera Therapeutics, Inc. (KYMR) | Director | Aug 20, 2020 | Jun 25, 2026 |
| Dianthus Therapeutics, Inc. (DNTH) | Former Director | Jun 20, 2018 | Jun 30, 2022 |
Also a director at
Kymera Therapeutics, Inc. (KYMR), Dianthus Therapeutics, Inc. (DNTH) (no filing in the last 18 months)
Recent filings
The last 2 days with transactions, newest first, one line per trade date. Each number links to an SEC filing.
- Aug 7, 2026, Spyre Therapeutics, Inc.: sold 23,000 shares for $2.4M, under a disclosed plan; 5,000 shares acquired by exercising options (some held indirectly). 1 filing: 1
- Dec 8, 2025, Kymera Therapeutics, Inc.: sold 5,000 shares for $449K, under a disclosed plan; 5,000 shares acquired by exercising options. 1 filing: 1
This page shows only what this person reported on SEC ownership filings. See the methodology. Spotted something wrong? Report an error.